Trial reportPharmacogenomics2017
Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.
Trial report in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Community pharmacy interventions for health promotion: effects on professional practice and health outcomes.The Cochrane database of systematic reviews · 2019Pooled it
- Article
- Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.Pharmacogenomics and personalized medicine · 2021Article
- Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-Pharmacogenomics and personalized medicine · 2021Review
- Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting.Pharmacogenomics and personalized medicine · 2021Article
- Community-Based Pharmacy Practice Innovation and the Role of the Community-Based Pharmacist Practitioner in the United States.Pharmacy (Basel, Switzerland) · 2019Review
- Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.Molecular biology reports · 2019Article
- Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.Journal of the American Pharmacists Association : JAPhAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimTo describe the rationale and design of a study evaluating the delivery of pharmacogenetic (PGx) testing in community pharmacies. Study rationale: Pharmacists have expressed interest in offering PGx testing; however, their lack of knowledge and experience, patients' acceptance and feasibility are unknown in this setting. STUDY
designThrough a cluster randomized trial, we will assess pharmacist and patient experiences with delivery of PGx testing as a standalone service or integrated into medication therapy management services. Anticipated results: We anticipate that PGx testing can be delivered in a community pharmacy setting and accepted and valued by patients.
conclusionThis study is expected to provide valuable evidence about the real-world feasibility and acceptance of a community pharmacist-delivered approach of PGx testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.